Ruxolitinib

Primary Myelofibrosis

OHSU Knight Cancer InstituteSmall moleculePhase 4 / ApprovedActive

BBB

73/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 59/ 100
Competitive Position: 95/ 100

Competitive context

13 Active assets in the Primary Myelofibrosis cohort.

Asset / Sponsor	Phase	Rating
TACROLIMUS City of Hope Medical Center	Phase 2	BB
Fludarabine University of Utah	Phase 2	BB
Panobinostat OHSU Knight Cancer Institute	Phase 4	BB
Busulphan University of Utah	Phase 2	B
Cyclophosphamide City of Hope Medical Center	Phase 2	B

View all 50 →

Same molecule, other indications

Ruxolitinib is also rated in:

graft versus host diseaseDormant

BB

Indicative ·

70 / 100

disease related to hematopoietic stem cell transplantDormant

BB

Indicative ·

70 / 100

acquired polycythemia veraDormant

BB

Indicative ·

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.